ValGenesis, Inc., the global leader in enterprise validation lifecycle management, will showcase its AI-powered ValGenesis Smart GxP™ Platform at the ISPE Annual Meeting & Expo, October 26–29 in Charlotte, North Carolina. At Booth #925, attendees can experience live demonstrations of the platform and receive complimentary access to the ARC Advisory Group’s latest report, “Accelerating Innovation and Time to Market in Life Sciences through AI-Powered Validation.” This exclusive report, typically available only to ARC clients, offers insights into how artificial intelligence is transforming validation from a time-consuming, compliance-heavy process into a strategic enabler of speed, accuracy, and innovation. The ValGenesis Smart GxP™ Platform integrates validation, quality, and manufacturing operations into a unified, AI-driven ecosystem. At its core are VAL™ Smart Agents—secure, lifecycle-governed AI models that automate critical tasks such as protocol authoring, risk assessments, anomaly detection, and compliance tracking. By leveraging intelligent automation and predictive analytics, the platform helps life sciences organizations achieve faster validation cycles, reduce rework, and maintain continuous audit readiness. It is designed to align with key global regulatory standards, including the FDA’s Computer Software Assurance (CSA) guidance, EU Annex 11, the EU AI Act, and ISPE GAMP 5 Second Edition. The platform’s development reflects a growing industry shift toward AI-driven digital transformation in regulated environments. ValGenesis recently launched a pilot program with select customers to test VAL™ Smart Agents in real-world validation workflows. These pilots aim to quantify tangible benefits such as time and cost savings, improved documentation consistency, and enhanced compliance readiness—providing concrete evidence of AI’s business value in highly regulated settings. Dave Medina, Chief Marketing Officer at ValGenesis, emphasized the practical evolution of AI in validation: “AI in validation is moving from concept to reality.” He noted that the pilot programs represent a pivotal moment where AI is being applied in actual operational environments, enabling companies to rethink the boundaries of what’s possible in validation. The ARC Advisory Group report, developed in collaboration with ValGenesis and informed by leading industry experts including Dr. Alton Johnson, Mr. José Caraballo Oramas, and Dr. José Vidal, underscores how AI-powered validation platforms deliver measurable return on investment. It highlights the shift from reactive compliance to proactive, predictive control—allowing organizations to anticipate issues before they arise and maintain alignment with evolving regulatory expectations. ValGenesis has served the life sciences industry for nearly two decades, helping companies digitize commissioning, qualification, and validation processes across areas such as risk management, cleaning validation, continued process verification, and CMC development. The company’s mission is to reduce operational costs, improve compliance, and accelerate innovation through intelligent, scalable solutions. For more information, contact Lisa Weeks, ValGenesis Communications, at (+1) 510-445-0505 or [email protected]. The ISPE 2025 exhibit offers a unique opportunity for life sciences professionals to explore how AI is reshaping validation and to gain early access to insights that could redefine compliance and innovation in the industry. With real-world pilots underway and regulatory frameworks adapting to new technologies, ValGenesis is positioning itself at the forefront of a new era in digital validation.